Novelty Nobility expands manufacturing deal with AGC Biologics for NN4101 program
PUBT · 2d ago
Share
Listen to the news
- AGC Biologics expanded manufacturing agreement with Novelty Nobility to support process development, tech transfer, and GMP manufacturing for bispecific antibody candidate NN4101.
- Work slated for Chiba, Japan site, following completed cell line development in Copenhagen, Denmark.
- NN4101 targets neovascular retinal diseases, combining fully human anti-c-Kit monoclonal antibody with VEGF trap.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AGC Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605032000PRIMZONEFULLFEED9711559) on May 04, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending